Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

p21 is a universal inhibitor of cyclin kinases

Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage

Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967

Computational identification of novel piperidine derivatives as potential HDM2 inhibitors designed by fragment-based QSAR, molecular docking and molecular dynamics simulations

Singh, A. P., Goyal, S., Jamal, S., Subramani, B., Das, M., Admane, N., & Grover, A. (2015) · Structural Chemistry · doi:10.1007/s11224-015-0697-2 · Cited by 25

Murine Double Minute-2 Inhibition Attenuates Cardiac Dysfunction and Fibrosis by Modulating NF-κB Pathway After Experimental Myocardial Infarction

Zhao, H., Shen, R., Dong, X., & Shen, Y. (2016) · Inflammation · doi:10.1007/s10753-016-0473-5 · Cited by 24

Pharmacological targeting of mutant p53

Kogan, S., & Carpizo, D. R. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.74 · Cited by 24

USP22‐mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression

Ren, D., Sun, Y., Li, D., Wu, H., & Jin, X. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13137 · Cited by 24

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Senapati, J., Müftüoğlu, M., Ishizawa, J., Abbas, H. A., Loghavi, S., Borthakur, G. M., Yilmaz, M. E., Issa, G. C., Dara, S., Basyal, M., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00871-1 · Cited by 25

Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling

Pishas, K. I., Neuhaus, S. J., Clayer, M., SCHREIBER, A. W., Lawrence, D., Perugini, M., Whitfield, R. J., Farshid, G., Manavis, J., Chryssidis, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2424 · Cited by 24

Induction of p53 suppresses chronic myeloid leukemia

Peterson, L. F., Lo, M., Liu, Y., Giannola, D. M., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J., & Talpaz, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272682 · Cited by 24

An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data

Sugaya, N., Ikeda, K., Tashiro, T., Takeda, S., Otomo, J., Ishida, Y., Shiratori, A., Toyoda, A., Noguchi, H., Takeda, T., et al. (2007) · BMC Pharmacology · doi:10.1186/1471-2210-7-10 · Cited by 24

p53 in breast cancer: mutation and countermeasures

Kumar, S. R. (2007) · Frontiers in bioscience · doi:10.2741/2378 · Cited by 24

Decision-making by p53 and mTOR

Maki, C. G. (2010) · Aging · doi:10.18632/aging.100166 · Cited by 24

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma

Hanes, R., Grad, I., Lorenz, S., Stratford, E. W., Munthe, E., Reddy, C. C. S., Meza‐Zepeda, L. A., & Myklebost, O. (2016) · Oncotarget · doi:10.18632/oncotarget.10518 · Cited by 23

Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma

Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C. E., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0710 · Cited by 26

DHX30 Coordinates Cytoplasmic Translation and Mitochondrial Function Contributing to Cancer Cell Survival

Bosco, B., Rossi, A., Rizzotto, D., Hamadou, M. H., Bisio, A., Giorgetta, S., Perzolli, A., Bonollo, F., Gaucherot, A., Catez, F., et al. (2021) · Cancers · doi:10.3390/cancers13174412 · Cited by 23

Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes

Gomes, N. P., & Espinosa, J. M. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12998 · Cited by 24

p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a

Duan, L., Perez, R. E., Chen, L., Blatter, L. A., & Maki, C. G. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx051 · Cited by 24

The Scandinavian Sarcoma Group

Alvegård, T. A., Hall, K. S., Bauer, H. C. F., & Rydholm, A. (2009) · Acta Orthopaedica · doi:10.1080/17453690610046602 · Cited by 23

Epitope‐specificity of recombinant antibodies reveals promiscuous peptide‐binding properties

Olsson, N., Wallin, S., James, P., Borrebaeck, C. A. K., & Wingren, C. (2012) · Protein Science · doi:10.1002/pro.2173 · Cited by 22

Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies

Bandaru, S., Ponnala, D., Lakkaraju, C., Bhukya, C. K., Shaheen, U., & Nayarisseri, A. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3759 · Cited by 22

The pseudo-caspase FLIP(L) regulates cell fate following p53 activation

Lees, A., McIntyre, A. J., Crawford, N., Falcone, F., McCann, C. K., Holohan, C., Quinn, G. P., Roberts, J. Z., Sessler, T., Gallagher, P. F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2001520117 · Cited by 22

Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma

Lanzi, C., Favini, E., Bo, L. D., Tortoreto, M., Arrighetti, N., Zaffaroni, N., & Cassinelli, G. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02150-y · Cited by 23

Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation

Tatavosian, R., Donovan, M. G., Galbraith, M. D., Duc, H. N., Szwarc, M. M., Joshi, M. U., Frieman, A., Bilousova, G., Cao, Y., Smith, K. P., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01113-4 · Cited by 22

Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis

Ramaiah, M. J., Pushpavalli, S. N. C. V. L., Lavanya, A., Bhadra, K., Haritha, V., Patel, N., Tamboli, J. R., Kamal, Ä., Bhadra, U., & Pal‐Bhadra, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.018 · Cited by 23

A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma

Toki, S., Kobayashi, E., Yoshida, A., Ogura, K., Wakai, S., Yoshimoto, S., Yonemori, K., & Kawai, A. (2019) · The Bone & Joint Journal · doi:10.1302/0301-620x.101b6.bjj-2018-1207.r1 · Cited by 22

Use of p53 for therapy of human cancer

Almazov, V. P., Кочетков, Д. В., & Chumakov, P. M. (2007) · Molecular Biology · doi:10.1134/s0026893307060015 · Cited by 22

Molecular targeting of E3 ligases – a therapeutic approach for cancer

Lakshmanan, M., Bughani, U., Duraisamy, S., Diwan, M., Dastidar, S. G., & Ray, A. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.7.855 · Cited by 22

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3

Yang, P., Chen, W., Li, X., Eilers, G., He, Q., Liu, L., Wu, Y., Wu, Y., Yu, W., Fletcher, J. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8999 · Cited by 21

Role of E3 ubiquitin ligases in gastric cancer

Hou, Y., & Deng, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.786 · Cited by 21

Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches

Tzakos, A. G., Fokas, D., Johannes, C., Moussis, V., Hatzimichael, E. C., & Briasoulis, E. C. (2011) · Molecules · doi:10.3390/molecules16064408 · Cited by 21

Wild-Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell Survival

Mullany, L. K., Liu, Z., King, E. R., Wong, K., & Richards, J. S. (2012) · Endocrinology · doi:10.1210/en.2011-2131 · Cited by 21

Function of translationally controlled tumor protein (TCTP) in Eudrilus eugeniae regeneration

Subramanian, E. R., Daisy, N. G., Sudalaimani, D. K., Ramamoorthy, K., Balakrishnan, S., Christyraj, J. D. S., Arumugaswami, V., & Sivasubramaniam, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175319 · Cited by 21

Bioorthogonal Probes for the Study of MDM2‐p53 Inhibitors in Cells and Development of High‐Content Screening Assays for Drug Discovery

D’Alessandro, P. L., Buschmann, N., Kaufmann, M., Furet, P., Baysang, F., Brunner, R., Marzinzik, A. L., Vorherr, T. E., Stachyra, T., Ottl, J., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608568 · Cited by 21

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

Oyedele, A.-Q. K., Adelusi, T. I., Ogunlana, A. T., Adeyemi, R. O., Emmanuel, A. O., Babalola, M. O., Ashiru, M. A., Ayoola, I. J., & Boyenle, I. D. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05131-w · Cited by 21

p53 Family: Therapeutic Targets in Neuroblastoma

Wolter, J. K., Angelini, P., & Irwin, M. S. (2010) · Future Oncology · doi:10.2217/fon.09.176 · Cited by 22

Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism

Polański, R., Noon, A. P., Blaydes, J. P., Phillips, A., Rubbi, C. P., PARSONS, K. F., Vlatković, N., & Boyd, M. T. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.024 · Cited by 20

Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation

Seo, S., Hwang, C.-S., Choe, T., Hong, S., Yi, J. Y., Hwang, S., Lee, H.-G., Oh, S. T., Lee, Y., & Park, I. (2014) · Oncotarget · doi:10.18632/oncotarget.3100 · Cited by 20

Mouse modelling of the MDM2/MDMX−p53 signalling axis

Tackmann, N. R., & Zhang, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx006 · Cited by 21

Synergistic Effect of Nutlin-3 Combined with MG-132 on Schwannoma Cells Through Restoration of Merlin and p53 Tumour Suppressors

Chen, H., Xue, L., Huang, H., Wang, H., Zhang, X., Zhu, W., Wang, Z., Wang, Z., & Wu, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.042 · Cited by 20

Protein–protein interactions for cancer therapy

Harris, C. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510948103 · Cited by 20

Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation

Ma, T., Yamada, S., Ichwan, S. J. A., Iseki, S., Ohtani, K., Otsu, M., & Ikeda, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.161 · Cited by 19

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22

Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2

Ozaki, T., Nakamura, M., & Shimozato, O. (2015) · Biomolecules · doi:10.3390/biom5042854 · Cited by 18

MDM2 antagonist nutlin‐3a sensitizes tumors to V‐ATPase inhibition

Schneider, L. S., Ulrich, M. P., Lehr, T., Menche, D., Müller, R., & von Schwarzenberg, K. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.005 · Cited by 19

[The use of p53 as a tool for human cancer therapy].

Almazov, V. P., Кочетков, Д. В., & Chumakov, P. M. (2007) · PubMed · Cited by 20

Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway

Lee, S., Choi, H. C., Choe, Y.-J., Shin, S. J., Lee, S. H., & Kim, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2463 · Cited by 18

A Fluorescent-Based High-Throughput Screening Assay for Small Molecules That Inhibit the Interaction of MdmX with p53

Tsuganezawa, K., Nakagawa, Y., Kato, M., Taruya, S., Takahashi, F., Endoh, M., Utata, R., Mori, M., Ogawa, N., Honma, T., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112460729 · Cited by 19

Cyclodipeptide c(Orn-Pro) Conjugate with 4-Ethylpiperic Acid Abrogates Cancer Cell Metastasis through Modulating MDM2

Shankar, S., Faheem, M. M., Nayak, D., Wani, N. A., Farooq, S., Koul, S., Goswami, A., & Rai, R. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00670 · Cited by 18

MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation

Sarısözen, C., Tan, Y., Liu, J. Y., Bilir, C., Shen, L., Filipczak, N., Porter, T. M., & Torchilin, V. P. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1570518 · Cited by 19

In Silico Peptide Ligation: Iterative Residue Docking and Linking as a New Approach to Predict Protein-Peptide Interactions

Diharce, J., Cueto, M., Beltramo, M., Aucagne, V., & Bonnet, P. (2019) · Molecules · doi:10.3390/molecules24071351 · Cited by 19

DNA damage response and development of targeted cancer treatments

Gasser, S. (2007) · Annals of Medicine · doi:10.1080/07853890701436773 · Cited by 18

MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

Hav, M., Libbrecht, L. J., Ferdinande, L., Pattyn, P., Laurent, S., Peeters, M., Praet, M. M., & Pauwels, P. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-1012-7 · Cited by 18

The small molecule AU14022 promotes colorectal cancer cell death via p53‐mediated G2/M‐phase arrest and mitochondria‐mediated apoptosis

Ryu, H., Nam, K., Kim, J., Hwang, S., Song, J. Y., & Ahn, J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26234 · Cited by 18

Recent translational research into targeted therapy for liposarcoma

Patel, R. B., Li, T., Liao, Z., Jaldeepbhai, J. A., Perera, H. A. P. N. V., Muthukuda, S. K., Dhirubhai, D. H., Singh, V. P., Du, X., & Yang, J. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.02.09 · Cited by 17

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways

Shimazu, K., Tada, Y., Morinaga, T., Shingyoji, M., Sekine, I., Shimada, H., Hiroshima, K., Namiki, T., Tatsumi, K., & Tagawa, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3300-y · Cited by 17

The role of SIRT5 and p53 proteins in the sensitivity of colon cancer cells to chemotherapeutic agent 5-Fluorouracil

Ekremoglu, O., & Koç, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06558-9 · Cited by 17

Intra Q-body: an antibody-based fluorogenic probe for intracellular proteins that allows live cell imaging and sorting

Dai, Y., Sato, Y., Zhu, B., Kitaguchi, T., Kimurâ, H., Ghadessy, F. J., & Ueda, H. (2022) · Chemical Science · doi:10.1039/d2sc02355e · Cited by 18

Harnessing p53 for targeted cancer therapy: new advances and future directions

Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 19

The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses

Salinas-Souza, C., de Oliveira, R., Alves, M. T. D. S., Jesús-García, R., Petrilli, A. S., & de Toledo, S. R. C. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.04.013 · Cited by 17

Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells

Fan, Y., Ma, K., Jing, J., Wang, C., Hu, Y., Shi, Y., Li, E., & Geng, Q. (2019) · Journal of Cancer · doi:10.7150/jca.32765 · Cited by 18

Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway

Lehmann, B. D., McCubrey, J. A., & Terrian, D. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4544 · Cited by 17

MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis

Sugano, N., Suda, T., Godai, T., Tsuchida, K., Shiozawa, M., Sekiguchi, H., Yoshihara, M., Matsukuma, S., Sakuma, Y., Tsuchiya, E., et al. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20774 · Cited by 17

Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence

Lieschke, E., Wang, Z., Chang, C. W. T., Weeden, C. E., Kelly, G. L., & Strasser, A. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00964-7 · Cited by 16

Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53–MDM2 interaction

Zhang, L., Zhang, J., Hu, C., Cao, J., Zhou, X., Hu, Y., He, Q., & Yang, B. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832aa7b0 · Cited by 16

Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53

Choe, Y.-J., Lee, S.-Y., Ko, K. W., Shin, S. J., & Kim, H.-S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2227 · Cited by 16

p53-Mediated Gene Activation in Mice at High Doses of Chronic Low-Dose-Rate γ Radiation

Sugihara, T., Murano, H., Nakamura, M. M., Ichinohe, K., & Tanaka, K. J. (2010) · Radiation Research · doi:10.1667/rr2446.1 · Cited by 16

XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer

Roh, J., Park, J. Y., & Kim, E. H. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1026-8 · Cited by 16

Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas

Sarek, G., Ma, L., Enbäck, J., Järviluoma, A., Moreau, P., Haas, J., Antoine Gessain, A., Koskinen, P. J., Laakkonen, P. M., & Ojala, P. M. (2012) · Oncogene · doi:10.1038/onc.2012.118 · Cited by 16

A fluorinated indole‐based MDM 2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells

Skalniak, Ł., Twarda‐Clapa, A., Neochoritis, C. G., Surmiak, E., Machula, M., Wiśniewska, A., Łabuzek, B., Ali, A. M., Krzanik, S., Dubin, G., et al. (2019) · FEBS Journal · doi:10.1111/febs.14774 · Cited by 16

A Novel Application for Murine Double Minute 2 Antagonists

Binder, B. R. (2007) · Circulation Research · doi:10.1161/01.res.0000255897.84337.38 · Cited by 16

Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies

Hinz, T. K., & Heasley, L. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.014 · Cited by 17

Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system

Amaral, J. D., Herrera, F., Rodrigues, P. M., Dionísio, P. A., Outeiro, T. F., & Rodrigues, C. M. P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.12.009 · Cited by 15

Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a

Duan, L., Perez, R. E., & Maki, C. G. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1523858 · Cited by 15

MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies

Roy, S., Laroche‐Clary, A., Verbeke, S., Derieppe, M., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12082253 · Cited by 15

Pulmonary artery intimal sarcoma – A primeval or rediscovered tumor? A report of 14 new cases with literature review

Qin, J., Ng, C. S., He, P., Lin, X., Lin, X.-N., & Hou, P. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153548 · Cited by 14

A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer

Miller, J. J., Kwan, K., Gaiddon, C., & Storr, T. (2022) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-022-01939-2 · Cited by 14

Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity

Abed, A. I., Greene, M. K., Alsa’d, A. A., Lees, A., Hindley, A., Longley, D. B., McDade, S. S., & Scott, C. J. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00926 · Cited by 15

Microfluidic Fabricated Liposomes for Nutlin-3a Ocular Delivery as Potential Candidate for Proliferative Vitreoretinal Diseases Treatment

Esposito, E., Pozza, E., Contado, C., Pula, W., Bortolini, O., Ragno, D., Toldo, S., Casciano, F., Bondi, A., Zauli, E., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s452134 · Cited by 14

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.548 · Cited by 14

An extra dimension in protein tagging by quantifying universal proteotypic peptides using targeted proteomics

Vandemoortele, G., Staes, A., Gonnelli, G., Samyn, N., Sutter, D. D., Vandermarliere, E., Timmerman, E., Gevaert, K., Martens, L., & Eyckerman, S. (2016) · Scientific Reports · doi:10.1038/srep27220 · Cited by 13

Application of bifurcation theory and siRNA-based control signal to restore the proper response of cancer cells to DNA damage

Kozłowska, E., & Puszyński, K. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.08.017 · Cited by 14

Pulmonary artery intimal sarcoma: A rare cause of filling defects in pulmonary arteries

Zhao, M., Nie, P., Guo, Y., & Chen, H. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.05.009 · Cited by 13

Ursodeoxycholic acid inhibits the uptake of cystine through SLC7A11 and impairs de novo synthesis of glutathione

Xie, F., Niu, Y., Chen, X., Kong, X., Yan, G., Zhuang, A., Li, X., Lian, L., Qin, D., Zhang, Q., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101068 · Cited by 14

Necdin, a p53-Target Gene, Is an Inhibitor of p53-Mediated Growth Arrest

Lafontaine, J., Rodier, F., Ouellet, V., & Mes‐Masson, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031916 · Cited by 13

p53 and nasopharyngeal carcinoma: a Malaysian study

Hoe, S., Lee, E. S., Khoo, A. S. B., & Peh, S. C. (2009) · Pathology · doi:10.1080/00313020903071504 · Cited by 13

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

Seyfried, I., Hofbauer, S. W., Stöcher, M., Greil, R., & Tinhofer, I. (2008) · Blood · doi:10.1182/blood-2008-05-158634 · Cited by 13

Tumor suppressor protein p53-mediated repression of human mitotic centromere-associated kinesin gene expression is exerted via down-regulation of Sp1 level

Jun, D. Y., Lee, J. Y., Park, H. S., Lee, Y. H., & Kim, Y. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189698 · Cited by 12

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

Chen, Y., Yang, P., Wang, J., Gao, S., Xiao, S., Zhang, W., Zhu, M., Wang, Y., Ke, X., & Jing, H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00381-7 · Cited by 12

Poroptosis: A form of cell death depending on plasma membrane nanopores formation

Li, H., Wang, Z., Fang, X., Zeng, W., Yang, Y., Jin, L., Wei, X., Qin, Y., Wang, C., & Liang, W. P. (2022) · iScience · doi:10.1016/j.isci.2022.104481 · Cited by 12

The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis

Davaadelger, B., Perez, R. E., Zhou, Y., Duan, L., Gitelis, S., & Maki, C. G. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1345397 · Cited by 12

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

Zonneville, J., Wang, M., Alruwaili, M., Smith, B. E., Melnick, M., Eng, K. H., Melendy, T., Park, B. H., Iyer, R. V., Fountzilas, C. K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02370-0 · Cited by 13

Differential regulation of p21 waf1 protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications

Chang, L.-J., & Eastman, A. R. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21047 · Cited by 12

Counteracting MDM2‐induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells

Nardinocchi, L., Puca, R., Givol, D., & D’Orazi, G. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.09.018 · Cited by 12

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level

Psatha, K., Kollipara, L., Drakos, E., Deligianni, E., Brintakis, K., Patsouris, E., Sickmann, A., Rassidakis, G. Z., & Aivaliotis, M. (2023) · Cancers · doi:10.3390/cancers15153903 · Cited by 11

Interaction of p53 with the Δ133p53α and Δ160p53α isoforms regulates p53 conformation and transcriptional activity

Tomas, F., Roux, P., & Gire, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07213-4 · Cited by 11

TAK1 signaling regulates p53 through a mechanism involving ribosomal stress

Zonneville, J., Wong, V., Limoge, M., Nikiforov, M. A., & Bakin, A. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59340-5 · Cited by 12

Microbial influences on hormesis, oncogenesis, and therapy: A review of the literature

Clanton, R., Saucier, D., Ford, J. R., & Akabani, G. (2015) · Environmental Research · doi:10.1016/j.envres.2015.06.026 · Cited by 12

DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a

Zhou, Y., Perez, R. E., Duan, L., & Maki, C. G. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1433500 · Cited by 11

Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas

Thomas, C. Y., & Theodorescu, D. (2006) · World Journal of Urology · doi:10.1007/s00345-006-0119-6 · Cited by 11

Emerging pharmacotherapies for elderly acute myeloid leukemia patients

Thomas, X., Elhamri, M., & Heiblig, M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1758058 · Cited by 11

The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins

Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 11

Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies

Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 14

Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy

Vassilev, L. T. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-sy18-01

Abstract 977: Elevated MDM2 protein contributes to activity of MDM2 antagonists by enabling p53 induction of antitumor microRNAs

Xia, M., Huang, B., Chu, W., & Vassilev, L. T. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-977

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics

Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271

Elevated MDM2 contributes to antitumor activity of p53-MDM2 binding inhibitors

Xia, M., Knezevic, D., Tovar, C., Heimbrook, D. C., & Vassilev, L. T. (2007) · Molecular Cancer Therapeutics

Abstract C128: Small-molecule antagonists of MDM2 and MDMX.

Thompson, T., Graves, B. J., Xia, M., Janson, C. A., Lukacs, C., Deo, D. D., Huang, K., Tovar, C., Lovey, A. J., Wanner, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c128